Correction to: Blood Cancer Journal
https://doi.org/10.1038/bcj.2017.29 published online 7 April 2017
Following the publication of this article the authors noted that Grant numbers were omitted in the Acknowledgements section. This work was supported by grants from the Cancer Research Society of Canada (grants no. 16255 to M.G.) and from the Fond de Recherche Santé Québec (grant no 20219 to J.R.) and in part by the Foundation de l’Hôpital Maisonneuve-Rosemont, Montreal, QC, CAN. The authors wish to apologize for any inconvenience caused.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Thiant, S., Moutuou, M.M., Laflamme, P. et al. Correction: Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients. Blood Cancer J. 10, 112 (2020). https://doi.org/10.1038/s41408-020-00374-3
Published:
DOI: https://doi.org/10.1038/s41408-020-00374-3
